Janus Henderson Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $48.4M | Buy |
857,010
+580,680
| +210% | +$33.9M | 0.02% | 420 |
|
|
2025
Q4 | $16.4M | Buy |
276,330
+39,302
| +17% | +$2.14M | 0.01% | 643 |
|
|
2025
Q3 | $12.8M | Buy |
237,028
+225,592
| +1,973% | +$12.9M | 0.01% | 705 |
|
|
2025
Q2 | $628K | Sell |
11,436
-480
| -4% | -$28.3K | ﹤0.01% | 1829 |
|
|
2025
Q1 | $851K | Hold |
11,916
| – | – | ﹤0.01% | 1701 |
|
|
2024
Q4 | $783K | Sell |
11,916
-2,135
| -15% | -$143K | ﹤0.01% | 1808 |
|
|
2024
Q3 | $987K | Hold |
14,051
| – | – | ﹤0.01% | 1674 |
|
|
2024
Q2 | $1.16M | Sell |
14,051
-682,467
| -98% | -$56.8M | ﹤0.01% | 1554 |
|
|
2024
Q1 | $60.8M | Sell |
696,518
-2,093,825
| -75% | -$187M | 0.03% | 346 |
|
|
2023
Q4 | $269M | Sell |
2,790,343
-634,196
| -19% | -$56.1M | 0.16% | 143 |
|
|
2023
Q3 | $303M | Buy |
3,424,539
+34,893
| +1% | +$3.1M | 0.2% | 124 |
|
|
2023
Q2 | $294M | Sell |
3,389,646
-47,638
| -1% | -$4.48M | 0.18% | 132 |
|
|
2023
Q1 | $334M | Sell |
3,437,284
-451,160
| -12% | -$46.8M | 0.22% | 112 |
|
|
2022
Q4 | $402M | Sell |
3,888,444
-4,371,004
| -53% | -$410M | 0.29% | 90 |
|
|
2022
Q3 | $700M | Buy |
8,259,448
+4,058,215
| +97% | +$361M | 0.26% | 100 |
|
|
2022
Q2 | $348M | Sell |
4,201,233
-158,551
| -4% | -$12.6M | 0.24% | 113 |
|
|
2022
Q1 | $336M | Buy |
4,359,784
+465,547
| +12% | +$39M | 0.16% | 148 |
|
|
2021
Q4 | $344M | Sell |
3,894,237
-54,444
| -1% | -$4.49M | 0.14% | 162 |
|
|
2021
Q3 | $305M | Sell |
3,948,681
-5,509
| -0.1% | -$435K | 0.13% | 176 |
|
|
2021
Q2 | $330M | Sell |
3,954,190
-1,039,465
| -21% | -$82.4M | 0.14% | 172 |
|
|
2021
Q1 | $377M | Sell |
4,993,655
-693,287
| -12% | -$56.6M | 0.17% | 132 |
|
|
2020
Q4 | $499M | Buy |
5,686,942
+472,232
| +9% | +$37.4M | 0.23% | 103 |
|
|
2020
Q3 | $397M | Buy |
5,214,710
+3,618,749
| +227% | +$366M | 0.21% | 113 |
|
|
2020
Q2 | $197M | Buy |
1,595,961
+463,882
| +41% | +$46.1M | 0.11% | 195 |
|
|
2020
Q1 | $95.7M | Buy |
1,132,079
+1,078,721
| +2,022% | +$92.9M | 0.07% | 295 |
|
|
2019
Q4 | $4.51M | Sell |
53,358
-1,504
| -3% | -$114K | ﹤0.01% | 1068 |
|
|
2019
Q3 | $3.7M | Sell |
54,862
-751
| -1% | -$57.8K | ﹤0.01% | 1093 |
|
|
2019
Q2 | $4.76M | Buy |
55,613
+9,953
| +22% | +$851K | ﹤0.01% | 1049 |
|
|
2019
Q1 | $4.05M | Buy |
45,660
+812
| +2% | +$75.3K | ﹤0.01% | 1037 |
|
|
2018
Q4 | $3.82M | Sell |
44,848
-157
| -0.3% | -$14.9K | ﹤0.01% | 1007 |
|
|
2018
Q3 | $4.37M | Buy |
45,005
+501
| +1% | +$50K | ﹤0.01% | 1057 |
|
|
2018
Q2 | $4.19M | Hold |
44,504
| – | – | ﹤0.01% | 1045 |
|
|
2018
Q1 | $3.61M | Hold |
44,504
| – | – | ﹤0.01% | 1065 |
|
|
2017
Q4 | $3.97M | Hold |
44,504
| – | – | ﹤0.01% | 1018 |
|
|
2017
Q3 | $4.14M | Buy |
44,504
+11,318
| +34% | +$1M | ﹤0.01% | 1002 |
|
|
2017
Q2 | $3.01M | Buy |
33,186
+10,976
| +49% | +$999K | ﹤0.01% | 1054 |
|
|
2017
Q1 | $1.95M | Hold |
22,210
| – | – | 0.01% | 504 |
|
|
2016
Q4 | $1.84M | Buy |
22,210
+2,607
| +13% | +$224K | 0.01% | 519 |
|
|
2016
Q3 | $1.81M | Hold |
19,603
| – | – | 0.01% | 494 |
|
|
2016
Q2 | $1.52M | Hold |
19,603
| – | – | 0.01% | 521 |
|
|
2016
Q1 | $1.62M | Hold |
19,603
| – | – | 0.01% | 525 |
|
|
2015
Q4 | $2.05M | Hold |
19,603
| – | – | 0.02% | 465 |
|
|
2015
Q3 | $2.06M | Hold |
19,603
| – | – | 0.02% | 466 |
|
|
2015
Q2 | $2.68M | Hold |
19,603
| – | – | 0.02% | 451 |
|
|
2015
Q1 | $2.44M | Buy |
19,603
+1,512
| +8% | +$160K | 0.02% | 481 |
|
|
2014
Q4 | $1.64M | Hold |
18,091
| – | – | 0.01% | 565 |
|
|
2014
Q3 | $1.3M | Hold |
18,091
| – | – | 0.01% | 536 |
|
|
2014
Q2 | $1.13M | Hold |
18,091
| – | – | 0.01% | 577 |
|
|
2014
Q1 | $1.23M | Buy |
18,091
+9,360
| +107% | +$690K | 0.01% | 547 |
|
|
2013
Q4 | $614K | Hold |
8,731
| – | – | 0.01% | 652 |
|
|
2013
Q3 | $631K | Hold |
8,731
| – | – | 0.01% | 643 |
|
|
2013
Q2 | $519K | Buy |
+8,731
| New | +$544K | 0.01% | 648 |
|
Other funds holding BMRN
VCM
VPM
Janus Henderson Group's BMRN Position: Q1 2026 in Review
Janus Henderson Group increased its BioMarin Pharmaceuticals (BMRN) stake by 210% in Q1 2026, buying an estimated $33.9M and bringing the position to 857,010 shares worth $48.4M. The position accounts for 0.02% of the portfolio, ranked #420.
Janus Henderson Group first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $700M in Q3 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Janus Henderson Group held 857,010 shares of BioMarin Pharmaceuticals worth $48.4M as of Q1 2026.
- Janus Henderson Group bought 580,680 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $33.9M.
- BioMarin Pharmaceuticals made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #420 holding.
- Janus Henderson Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Janus Henderson Group's BioMarin Pharmaceuticals position peaked at $700M in Q3 2022.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.